Core Viewpoint - Jiangsu Hengrui Medicine Co., Ltd. has successfully included several of its products in the National Medical Insurance Directory, which is expected to enhance the accessibility of its medications and potentially increase sales revenue [1] Group 1: Inclusion of Products - The following products have been newly included in the National Medical Insurance Directory: injection of Rukang Qutuzumab, Apixaban Famitinib Capsules, injection of Funaqi Zhumab, Sulfate Amasitinib Tablets, injection of Phosphorola Pitant Palonosetron, injection of Ruikasi Dantab, Acetate Abiraterone Tablets (II), Liposomal Irinotecan Injection (II), and Regaglitin Metformin Tablets (I)/(II), as well as Perfluorohexyl Octane Eye Drops [1] - New indications for the following products have also been successfully added: injection of Karilizumab, Fluorouracil Capsules, and injection of Fumaric Acid Tegafur [1] - The following products have successfully renewed their contracts to remain in the National Medical Insurance Directory: Maleate Pyrotinib Tablets, Hecorapam Ethanolamine Tablets, Phosphate Regaglitin Tablets, injection of Tanshinone IIA, and Sulfate Pevonedistat Injection [1] Group 2: Adjustments and Management - The indications for Methoxamine Apatinib Tablets and Bupivacaine Liposome Injection have been newly added and adjusted to regular directory management [1]

Core Viewpoint - Jiangsu Hengrui Medicine Co., Ltd. has successfully included several of its products in the National Medical Insurance Directory, which is expected to enhance market access and potentially increase sales revenue for the company [1] Group 1: Inclusion of Products - The following products have been newly included in the National Medical Insurance Directory: - Injection of Rukang Qutuzumab - Apixaban Famitinib Capsules - Injection of Funaqi Qutuzumab - Sulfate of Amagatin Tablets - Injection of Phosphororapitant Palonosetron - Injection of Ruikaxizumab - Acetate of Abiraterone Tablets (II) - Liposomal Injection of Irinotecan (II) - Regaglitin Metformin Tablets (I)/(II) - Perfluorohexyl Octane Eye Drops [1] - The following products have successfully added new indications to the National Medical Insurance Directory: - Injection of Karilizumab - Fluorouracil Capsules - Injection of Fumaric Acid Tegafur [1] - The following products have successfully renewed their contracts to remain in the National Medical Insurance Directory: - Maleate of Pyrotinib Tablets - Hecorapam Ethanolamine Tablets - Phosphate of Regaglitin Tablets - Injection of Tofisopam - Injection of Sulfapegfilgrastim [1] Group 2: Adjustments and Management - The following products have had new indications added and adjusted to regular directory management: - Mesylate of Apatinib Tablets - Liposomal Injection of Bupivacaine [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年12月7日 、馮佶 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生 女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025- ...

Group 1 - The top three companies with the highest short position ratios are Vanke Enterprises (02202) at 22.40%, COSCO Shipping Holdings (01919) at 16.93%, and ZTE Corporation (00763) at 15.67% [1][2] - The companies with the largest absolute increase in short position ratios are UBTECH Robotics (09880) with an increase of 3.27%, Vanke Enterprises (02202) with an increase of 2.80%, and SUTENG (02498) with an increase of 1.62% [1][2] - The companies with the largest absolute decrease in short position ratios are China Civil Aviation Information Network (00696) with a decrease of -5.36%, Beijing Enterprises Water Group (00371) with a decrease of -2.98%, and China Resources Pharmaceutical Group (03320) with a decrease of -1.79% [1][3] Group 2 - The top ten companies with the highest short position ratios include Heng Rui Medicine (01276) at 15.64%, Ping An Insurance (02318) at 13.35%, and Dongfang Electric (01072) at 13.01% [2] - The companies with the largest increase in short position ratios also include Dongfeng Motor Group (00489) with an increase of 1.37% and Dongfang Electric (01072) with an increase of 1.36% [2] - The companies with the largest decrease in short position ratios also include China Everbright Bank (06818) with a decrease of -1.63% and Xiehe New Energy (00182) with a decrease of -1.09% [3][4]

朱国新是恒瑞医药今年引入的第二位跨国药企核心高管，或将 成为这家公司的7号人物。 作者： 刘晓诺 封图：图虫创意 想出海的"医药一哥"，正不断引进有海外经验的"船长"和"大副"。 2025年12月3日，恒瑞医药（600276.SH/01276.HK）宣布提名聘任朱国新为高级副总裁。公开信 息显示，加入恒瑞之前，朱国新曾是跨国公司礼来的新药研发中心副总裁。 胡新辉任副总裁与首席技术官。据公开资料，2005—2018年，胡新辉曾在葛兰素史克、默沙东、 强生、罗氏上海研发中心等多家跨国药企任职。此后，他先后担任云顶新耀（01952.HK）首席技 术官、凯莱英（002821.SZ/06821.HK）首席技术官兼首席商务官。 孙志刚任副总裁与首席质量官。加入恒瑞医药之前，他是绿叶制药（02186.HK）集团高级副总 裁。他曾在美国FDA工作近12年，负责药品质量审评和GMP现场检查等工作。 尹航任副总裁与肿瘤事业部总经理。他曾任职于诺和诺德，2019年加入礼来中国，2021年8月起任 礼来肿瘤事业部副总裁，直至2025年9月离任。 此外，10月10日，恒瑞医药控股的互联网医疗公司医朵云也迎来新高管：前阿斯利康中国副总裁 ...

Core Insights - The article highlights the top and bottom AH share premium rates, with Northeast Electric (00042) leading at a premium of 900.00% and Ningde Times (03750) at the bottom with a premium of -4.97% [1][2][3] Group 1: Top AH Share Premium Rates - Northeast Electric (00042) has the highest premium rate of 900.00% with a deviation value of 33.66% [1][4] - Hongye Futures (03678) follows with a premium of 268.44% and a deviation value of 3.75% [2][4] - Sinopec Oilfield Service (01033) ranks third with a premium of 264.47% and a deviation value of 0.08% [1][2] Group 2: Bottom AH Share Premium Rates - Ningde Times (03750) has the lowest premium rate at -4.97% with a deviation value of 5.61% [3][5] - China Merchants Bank (03968) has a premium of -3.09% and a deviation value of -2.65% [3][5] - Heng Rui Medicine (01276) shows a premium of 0.15% with a deviation value of -3.16% [3][5] Group 3: Top Deviation Values - Northeast Electric (00042) leads with a deviation value of 33.66% [1][4] - Guanghetong (00638) has a deviation value of 30.36% [4] - Beijing Jingcheng Machinery (00187) follows with a deviation value of 23.74% [4] Group 4: Bottom Deviation Values - GAC Group (02238) has the lowest deviation value at -24.07% [5] - Jiangsu Ninghu Highway (00177) shows a deviation value of -18.32% [5] - Shenzhen Expressway (00548) has a deviation value of -11.27% [5]

一位上市创新药企董事长对经济观察报说："朱国新应该算华人在跨国药企中位子比较高的人了。这个人口碑相当不错，年纪也正当年，应该是1968-1969年 出生。我觉得对今天的恒瑞是一个很好的选择。" 朱国新是恒瑞医药今年引入的第二位跨国药企核心高管。4月，冯佶成为恒瑞医药近年引进的首位跨国药企中国区"一把手"。 她生于1970年，曾就职于上海仁济医院、诺华和安万特。此后，冯佶在阿斯利康工作20多年，曾担任中国区总经理、亚洲区区域副总裁、全球商业洞察与卓 越业务高级副总裁等职务。 10月，恒瑞医药还官宣了三位新任副总裁，均有海外背景： 胡新辉任副总裁与首席技术官。据公开资料，2005—2018年，胡新辉曾在葛兰素史克、默沙东、强生、罗氏上海研发中心等多家跨国药企任职。此后，他先 后担任云顶新耀（01952.HK）首席技术官、凯莱英（002821.SZ/06821.HK）首席技术官兼首席商务官。 经济观察报 记者 刘晓诺 想出海的"医药一哥"，正不断引进有海外经验的"船长"和"大副"。 2025年12月3日，恒瑞医药（600276.SH/01276.HK）宣布提名聘任朱国新为高级副总裁。公开信息显示，加入恒瑞之前，朱国 ...

Core Insights - The article highlights the top and bottom AH premium rates for various stocks, indicating significant disparities in market valuations between A-shares and H-shares [1][2] - Northeast Electric (00042) leads with a premium rate of 900.00%, while CATL (03750) shows a negative premium rate of -4.93%, suggesting potential investment opportunities and risks [1] AH Premium Rate Rankings - The top three stocks with the highest AH premium rates are: - Northeast Electric (00042) with a premium of 900.00% and a deviation value of 34.85% [1] - Hongye Futures (03678) with a premium of 272.56% and a deviation value of 8.87% [1] - Zhejiang Shibao (01057) with a premium of 261.81% and a deviation value of 5.38% [1] - The bottom three stocks with the lowest AH premium rates are: - CATL (03750) with a premium of -4.93% and a deviation value of 6.10% [1] - China Merchants Bank (03968) with a premium of -1.58% and a deviation value of -1.24% [1] - Heng Rui Medicine (01276) with a premium of 0.64% and a deviation value of -2.66% [1] Deviation Value Rankings - The top three stocks with the highest deviation values are: - Guanghetong (00638) with a deviation value of 36.62% [1] - Northeast Electric (00042) with a deviation value of 34.85% [1] - Beijing Machinery (00187) with a deviation value of 27.48% [1] - The bottom three stocks with the lowest deviation values are: - GAC Group (02238) with a deviation value of -20.57% [1] - Jiangsu Ninghu Highway (00177) with a deviation value of -13.89% [1] - Shenzhen Expressway (00548) with a deviation value of -12.04% [1]

Core Viewpoint - FTSE Russell announced adjustments to several indices, including the FTSE China 50 Index, FTSE China A50 Index, FTSE China A150 Index, FTSE China A200 Index, and FTSE China A400 Index, effective after the market close on December 19, 2025 [1][17]. Group 1: Index Adjustments - The FTSE China A50 Index will include Luoyang Molybdenum and Sungrow Power, while removing Jiangsu Bank and SF Holding [3][19]. - The FTSE China 50 Index will add China Hongqiao, CATL, and Heng Rui Medicine, and remove CITIC Securities, Great Wall Motors, and Li Auto [5][21]. - The FTSE China A150 Index will add Ying Shi Innovation, Jiangsu Bank, Huadian New Energy, SF Holding, Jiangbolong, and Huayou Cobalt, while removing Luoyang Molybdenum, Desay SV, Longi Green Energy, Baoxin Software, Shanghai Pharmaceuticals, and Sungrow Power [9][25]. - The FTSE China A200 Index will include Ying Shi Innovation, Huadian New Energy, Jiangbolong, and Huayou Cobalt, and exclude Desay SV, Longi Green Energy, Baoxin Software, and Shanghai Pharmaceuticals [11][27]. - The FTSE China A400 Index will see a broader adjustment, adding Anji Technology, Baiyin Nonferrous Metals, Yitang Co., and BlueFocus, while removing Chipbond Technology, Yipin Hong, Guanghuan Xin, and Huaxi Biological [12][28]. Group 2: Investment Implications - The adjustments by FTSE Russell are expected to attract passive fund allocations to the included stocks and increase overseas interest in Chinese assets [15][31]. - In the first ten months of 2025, foreign capital inflow into the Chinese stock market reached $50.6 billion, significantly surpassing the $11.4 billion for the entire year of 2024, marking an increase of over three times [15][31]. - UBS forecasts that the A-share market will see an increase in earnings growth from 6% this year to 8% next year, driven by improved nominal GDP growth and a narrowing of PPI declines [16][32]. - Morgan Stanley has set a target for the CSI 300 Index at 4,840 points by December 2026, indicating a stable outlook for Chinese stocks amid moderate earnings growth and higher valuation levels [16][32].

Core Viewpoint - Heng Rui Medicine (01276) announced the appointment of Zhu Guoxin as the Senior Vice President, effective from the date of the board meeting approval until the current board's term ends [1] Group 1 - The board of directors approved the proposal for the appointment of a Senior Vice President [1] - The appointment is based on the company's operational development needs [1]